Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ocular drug delivery
Pharma
Glaukos beats path to FDA after eye implant trials hit goals
Glaukos found the implant was non-inferior to an active control, twice-daily topical timolol ophthalmic solution, in glaucoma and ocular hypertension.
Nick Paul Taylor
Sep 13, 2022 8:45am
Glaukos pays iVeena $10M for eye drop vision loss candidate
Aug 30, 2022 10:05am
Kala buys time by selling eye disease drugs to Alcon for $60M
May 24, 2022 10:35am
Salvat heads to regulators with phase 3 data on ocular steroid
Apr 12, 2022 7:34am
Optifye and DelSiTech partner on controlled-release eye drops
Mar 29, 2022 7:50am
MediPrint raises cash to advance drug delivery contact lens
Mar 22, 2022 7:45am
